Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523 | 0.96 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL2505 | 0.94 | SMN1; SMN2 (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL102472 | 0.92 | POLB (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1972216 | 0.84 | TSHR (0.40) | MEN1KMT2AALDH1A1TSHRPOLB | |
| SCHEMBL1709463 | 0.84 | OPRM1 (0.48) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL873424 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL1283011 | 0.82 | OPRM1 (0.47) | MEN1KMT2AALDH1A1TSHRPOLB | |
| SCHEMBL15166914 | 0.82 | POLB (0.38) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1709447 | 0.81 | OPRM1 (0.35) | SMN1; SMN2KMT2AALDH1A1TSHRGAA | |
| SCHEMBL9606533 | 0.81 | CYP1A2 (0.40) | SMN1; SMN2ALDH1A1GAAPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-4622712-A1 | SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2 | Vertex Pharmaceuticals Incorporated (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119241408-A | Trifluoro methyl sulfide molecule as HIF2a inhibitor | 维眸生物科技(浙江)有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| EP-1730143-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
| EP-1656340-A1 | 1-CARBAMOYLCYCLOALKYLCARBOXYLIC ACID COMPOUNDS, PROCESSES FOR MAKING AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005094531-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050085544-A1 | Cycloalkylamidoacid compounds, processes for making and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| WO-2005019158-A1 | 1-CARBAMOYLCYCLOALKYLCARBOXYLIC ACID COMPOUNDS, PROCESSES FRO MAKING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-03 | — | — | WO | disclosed |
| US-3954730-A | ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SMN1; SMN2 782/4885MEN1 2259/4885KMT2A 3318/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | SMN1; SMN2 787/4885MEN1 2268/4885KMT2A 3301/4885 |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | SMN1; SMN2 3333/4885MEN1 3874/4885KMT2A 2054/4885 |
| US-20050085544-A1 | Cycloalkylamidoacid compounds, processes for making and uses thereof | ACMSD, QPCT, DCXR | SMN1; SMN2 4631/4885MEN1 3653/4885KMT2A 3683/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | SMN1; SMN2 782/4885MEN1 2259/4885KMT2A 3318/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | SMN1; SMN2 3385/4885MEN1 1917/4885KMT2A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.